Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Combined therapy with intravitreal bevacizumab and posterior subtenon triamcinolone acetonide injection in diabetic macular oedema.

Kim HD, Kang KD, Choi KS, Rhee MR, Lee SJ.

Acta Ophthalmol. 2014 Nov;92(7):e589-90. doi: 10.1111/aos.12420. Epub 2014 May 27. No abstract available.

2.

Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.

Sheth S, Rush R, Natarajan S, Gillies M.

Clin Exp Ophthalmol. 2011 Sep-Oct;39(7):673-81. doi: 10.1111/j.1442-9071.2011.02504.x. Epub 2011 Mar 24.

PMID:
22452685
3.

Comparison of a single intravitreal injection of bevacizumab versus triamcinolone acetonide as primary treatment for diffuse diabetic macular oedema.

Penha FM, Maia M, Cardillo JA, Arevalo JF, Wu L, Rodriguez FJ, Berrocal MH, Farah ME; Pan-American Collaborative Retina Study.

Acta Ophthalmol. 2012 Mar;90(2):e160-1. doi: 10.1111/j.1755-3768.2010.02098.x. Epub 2011 Apr 6. No abstract available.

4.

Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection.

Kim MW, Moon H, Yang SJ, Joe SG.

Korean J Ophthalmol. 2016 Feb;30(1):25-31. doi: 10.3341/kjo.2016.30.1.25. Epub 2016 Jan 21.

5.

Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.

Rensch F, Spandau UH, Wickenhäuser A, Jonas JB.

Acta Ophthalmol. 2010 Mar;88(2):e36-7. doi: 10.1111/j.1755-3768.2008.01443.x. No abstract available.

6.

Short-term efficacy of intravitreal triamcinolone acetonide for bevacizumab-resistant diabetic macular oedema.

Kim JH, Lee TG, Lew YJ.

Acta Ophthalmol. 2015 Mar;93(2):e178-9. doi: 10.1111/aos.12504. Epub 2014 Jul 10. No abstract available.

7.

Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.

Kumar V, Ghosh B, Raina UK, Goel N.

Am J Ophthalmol. 2008 Dec;146(6):974; author reply 974-5. doi: 10.1016/j.ajo.2008.08.013. No abstract available.

PMID:
19027427
8.

Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.

Ding X, Li J, Hu X, Yu S, Pan J, Tang S.

Retina. 2011 May;31(5):838-45. doi: 10.1097/IAE.0b013e3181f4420d.

PMID:
21293319
9.

Diabetic macular oedema in 2011: what are the options for refractory cystic oedema?

Wickremasinghe S.

Clin Exp Ophthalmol. 2011 Sep-Oct;39(7):595-7. doi: 10.1111/j.1442-9071.2011.02662.x. No abstract available.

PMID:
22452678
10.

Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.

Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, Nishida K.

Am J Ophthalmol. 2008 May;145(5):854-61. doi: 10.1016/j.ajo.2007.12.031. Epub 2008 Mar 6.

PMID:
18328456
11.

Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab.

Jeon S, Lee WK.

Retina. 2014 Aug;34(8):1606-11. doi: 10.1097/IAE.0000000000000109.

PMID:
24553409
12.

Comparison of grid laser, intravitreal triamcinolone, and intravitreal bevacizumab in the treatment of diffuse diabetic macular edema.

Sobaci G, Ozge G, Erdurman C, Durukan HA, Bayraktar ZM.

Ophthalmologica. 2012;227(2):95-9. doi: 10.1159/000331322. Epub 2011 Sep 2.

PMID:
21893972
13.

Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.

Isaac DL, Abud MB, Frantz KA, Rassi AR, Avila M.

Acta Ophthalmol. 2012 Feb;90(1):56-60. doi: 10.1111/j.1755-3768.2009.01817.x. Epub 2009 Dec 16.

14.

Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.

Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA.

Retina. 2012 Feb;32(2):314-21. doi: 10.1097/IAE.0b013e31822f55de.

PMID:
22234244
15.

Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).

Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R.

Br J Ophthalmol. 2008 Jan;92(1):76-80. Epub 2007 Oct 26.

PMID:
17965109
16.
17.

Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.

Cheng KC, Wu WC, Chen KJ.

Eye (Lond). 2009 Nov;23(11):2023-33. doi: 10.1038/eye.2009.230. Epub 2009 Oct 2.

PMID:
19798117
18.

Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.

Akinci A, Muftuoglu O, Altınsoy A, Ozkılıc E.

Retina. 2011 Apr;31(4):755-8. doi: 10.1097/IAE.0b013e3182006da1.

PMID:
21124251
19.

Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.

Sonoda Y, Arimura N, Shimura M, Sakamoto T.

Retina. 2011 Feb;31(2):290-7. doi: 10.1097/IAE.0b013e3181eef070.

PMID:
21102366
20.

Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema.

Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY, Nam DH.

Am J Ophthalmol. 2011 Oct;152(4):686-94. doi: 10.1016/j.ajo.2011.03.033. Epub 2011 Jul 22.

PMID:
21782151

Supplemental Content

Support Center